Wegovy Weight Loss Calculator — Predict Your Results with Semaglutide 2.4mg
Wegovy (semaglutide 2.4mg) is the first FDA-approved once-weekly GLP-1 receptor agonist specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. In the landmark STEP-1 clinical trial, Wegovy helped participants lose an average of 14.9% of their body weight over 68 weeks. Use our free calculator to estimate your own projected weight loss timeline on Wegovy.
How Much Weight Can You Lose on Wegovy?
The most robust evidence for Wegovy comes from the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, a series of phase 3 randomized controlled trials designed specifically to evaluate semaglutide 2.4mg for weight management.
In the pivotal STEP-1 trial (PMID: 33567185), published in the New England Journal of Medicine in 2021, 1,961 adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) were randomized to receive either semaglutide 2.4mg or placebo via once-weekly subcutaneous injection for 68 weeks, alongside lifestyle intervention. The results were striking:
- Participants on semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group.
- For a person weighing 220 lbs (100 kg), this translates to approximately 33 lbs (15 kg) of weight loss.
- Over 86% of participants achieved at least 5% weight loss, and roughly one-third achieved 20% or more weight loss.
The broader STEP program included additional trials that further validated these findings across diverse populations. STEP-2 studied patients with type 2 diabetes, STEP-3 combined semaglutide with intensive behavioral therapy, and STEP-4 demonstrated that sustained treatment is essential to maintain weight loss. Across all STEP trials, semaglutide 2.4mg consistently demonstrated clinically meaningful weight loss coupled with improvements in cardiometabolic risk factors such as waist circumference, blood pressure, HbA1c, and lipid profiles.
Additionally, the SELECT trial (2023) showed that semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, giving Wegovy a unique cardiovascular benefit among weight management medications.
Wegovy Dosing Schedule
Wegovy follows a gradual dose-escalation (titration) schedule designed to minimize gastrointestinal side effects and improve tolerability. The dose increases every four weeks until the maintenance dose of 2.4mg is reached at week 17. Each dose is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm.
| Phase | Weeks | Weekly Dose | Purpose |
|---|---|---|---|
| Titration 1 | Week 1–4 | 0.25mg | Initial tolerance building |
| Titration 2 | Week 5–8 | 0.5mg | Early weight loss begins |
| Titration 3 | Week 9–12 | 1.0mg | Appetite suppression increases |
| Titration 4 | Week 13–16 | 1.7mg | Approaching therapeutic dose |
| Maintenance | Week 17+ | 2.4mg | Full therapeutic dose — maximum weight loss |
If you experience significant GI side effects at any dose, your healthcare provider may recommend staying at the current dose for an additional 4 weeks before escalating. The full 16-week titration is designed to help your body adjust gradually and reduce nausea and other digestive symptoms.
Wegovy vs Ozempic — What’s the Difference?
Wegovy and Ozempic are both manufactured by Novo Nordisk and contain the same active ingredient: semaglutide, a GLP-1 receptor agonist. Despite sharing the same molecule, they are approved for different indications and prescribed at different doses:
Wegovy (Semaglutide 2.4mg)
- Indication: FDA-approved for chronic weight management
- Max dose: 2.4mg once weekly
- Trial program: STEP trials (focused on weight loss outcomes)
- Avg weight loss: 14.9% over 68 weeks
- CV benefit: SELECT trial showed 20% reduction in MACE
Ozempic (Semaglutide 2.0mg)
- Indication: FDA-approved for type 2 diabetes
- Max dose: 2.0mg once weekly
- Trial program: SUSTAIN trials (focused on glycemic control)
- Avg weight loss: ~10–12% (as secondary outcome)
- Primary goal: Blood sugar control (HbA1c reduction)
The key difference is that Wegovy reaches a higher maintenance dose (2.4mg vs 2.0mg) and its clinical trial program (STEP) was designed from the outset to measure weight loss as the primary endpoint. Ozempic is frequently prescribed off-label for weight loss, but Wegovy is the version specifically developed, dosed, and approved for that purpose. If weight management is your primary goal, Wegovy is the indicated choice.
Want to see projected results for Ozempic specifically? Try our Ozempic Weight Loss Calculator.
Wegovy vs Mounjaro (Tirzepatide)
Wegovy and Mounjaro represent two different pharmacological approaches to weight management. Understanding their mechanisms and clinical data can help you and your healthcare provider make an informed decision.
Wegovy (Semaglutide)
- Mechanism: GLP-1 receptor agonist (single target)
- Avg weight loss: 14.9% (STEP-1, 68 weeks)
- Long-term data: More extensive — 4+ years of post-approval safety data
- CV outcomes: SELECT trial demonstrated cardiovascular benefit
- Manufacturer: Novo Nordisk
Mounjaro (Tirzepatide)
- Mechanism: Dual GIP/GLP-1 receptor agonist (two targets)
- Avg weight loss: 22.5% at 15mg (SURMOUNT-1, 72 weeks)
- Long-term data: Newer to market — less post-approval data available
- CV outcomes: SURPASS-CVOT ongoing
- Manufacturer: Eli Lilly
Tirzepatide (the active ingredient in Mounjaro and its weight-management counterpart, Zepbound) works by activating both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual-agonist mechanism is believed to enhance weight loss beyond what GLP-1 activation alone can achieve. In the SURMOUNT-1 trial (PMID: 35658024), participants on tirzepatide 15mg lost an average of 22.5% of their body weight over 72 weeks, compared to 14.9% with semaglutide 2.4mg in STEP-1.
However, Wegovy has important advantages. It has a longer track record with more extensive real-world safety data. The SELECT cardiovascular outcomes trial demonstrated that semaglutide reduces the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in people with overweight or obesity, making it the only GLP-1 medication with a proven cardiovascular benefit in this population. No comparable cardiovascular outcomes data yet exists for tirzepatide in a non-diabetic population.
The choice between Wegovy and Mounjaro depends on your individual health profile, insurance coverage, medication availability, and your healthcare provider’s recommendation. Both are powerful tools for managing obesity, and our calculator can help you model projected outcomes for either medication.
Common Wegovy Side Effects
Like all GLP-1 receptor agonists, Wegovy can cause side effects, particularly gastrointestinal symptoms. Most side effects are mild to moderate in severity and tend to decrease over time as the body adjusts to each dose level during the titration period. The following side effect rates were reported in the STEP-1 trial:
Most common in the first few weeks at each new dose
Usually transient and resolves without treatment
Can be reduced by eating smaller meals
Adequate hydration and fiber intake may help
Typically mild and resolves within the first month
Important: Serious but rare side effects include pancreatitis, gallbladder problems, and kidney injury. Wegovy carries a boxed warning for thyroid C-cell tumors observed in rodent studies (though this has not been confirmed in humans). Always discuss the full risk-benefit profile with your healthcare provider before starting treatment. Wegovy is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Ready to Predict Your Wegovy Results?
Our free calculator uses clinical trial data from the STEP program to generate a personalized week-by-week weight loss projection based on your starting weight, height, and age.
Try the GLP-1 Weight Loss Calculator